Oncology · Cellular Plasticity

Decoding Cancer Plasticity.
Defeating Therapy Resistance.

Kembi Therapeutics is pioneering a new class of oncology therapies targeting the biological mechanisms that allow cancer to escape treatment. Our work enables prevention and reversal of previously intractable therapy resistance across all tumour types.

Explore Our Science View Pipeline

Phase 2

Lead clinical program

mTNBC

Lead indication

Pan-Tumour

Platform breadth

Kembi Therapeutics Reports Positive Interim Data from Lead Clinical Program

24 April 2026

Kembi Therapeutics has reported positive interim results from the 4CAST clinical trial, testing whether blocking cancer cell plasticity can prevent chemotherapy resistance in patients with metastatic triple-negative breast cancer.

Early Clinical Signal:

67% objective response rate (4 of 6 patients)

Read Full Article

The Science

Why Plasticity?

Most oncology therapeutic approaches fight cancer after it has already adapted. We go further upstream.

The Plasticity Problem

Cancer doesn't fail treatment by chance. It adapts. Cellular plasticity (the ability of cells to change states) allows tumour cells to shift identity, evade targeted therapies, and seed resistant disease. This is the central unsolved problem in oncology.

Learn about our science

Our Approach

We directly target the plasticity machinery: the signals that enable cancer cells to change. By intervening at the source of adaptability, we aim to prevent resistance before it begins.

Mechanism focus

Pan-tumour platform Prevent cell state switching Prevent therapy resistance

Clinical Stage

Phase 2 mTNBC

Our lead compound KMB-464 (seviteronel) is currently in Phase 2 clinical trial for metastatic triple-negative breast cancer.

Platform

Pan-Tumour

Our identified plasticity mechanisms are conserved across multiple cancer types, giving Kembi a broad platform applicable beyond a single indication.

What sets us apart

Built for the hardest problem in oncology

First-in-Class Science

Built on two decades of research into the molecular drivers of cancer cell plasticity, a field Kembi's founder and CEO helped define.

View our publications

Clinical Stage

Phase 2 data in mTNBC with planned expansion into additional indications, backed by a robust translational program.

View our lead program

Platform Pipeline

Plasticity programs are conserved across cancer types. Kembi's discovery pipeline focuses on multiple ways of addressing resistance at its source.

View our pipeline

Forward-Looking Statements

This announcement contains forward-looking statements based on interim data from an early-phase clinical trial. Results are based on a small number of patients and may not be representative of outcomes in a larger population. These findings are preliminary and should not be interpreted as evidence of established efficacy. Further clinical investigation is ongoing. This announcement is for informational purposes only and does not constitute medical advice or an offer to invest in Kembi Therapeutics.

Decoding Cancer Plasticity. Defeating Therapy Resistance.

Kembi Therapeutics Reports Positive Interim Data from Lead Clinical Program

Why Plasticity?

The Plasticity Problem

Our Approach

Phase 2 mTNBC

Pan-Tumour

Built for the hardest problem in oncology

First-in-Class Science

Clinical Stage

Platform Pipeline

Interested in partnering or investing?

Forward-Looking Statements

Decoding Cancer Plasticity.
Defeating Therapy Resistance.